Tiffany P. Olson
Independent DirectorMs. Tiffany P. Olson, MBA (Minnesota), BSB (Minnesota), was Independent Chairman of the Board of Telix Pharmaceuticals Limited from May 21, 2025 until February 3, 2026 and served as its Independent Non-Executive Director since March 31, 2022 until February 3, 2026. She serves as Independent Director of MiMedx Group, Inc since March 1, 2024. She serves as Director at Castle Biosciences, Inc. since May 11, 2021. She serves as the Member of Advisory Board at Future Enterprises, Inc. She was a President, Nuclear & Precision Health Solutions at Cardinal Health, Inc. from July 2013 to October 2021. She served as a Director of BioTelemetry, Inc. since February 28, 2019 until 2020. She served as President of Nuclear Pharmacy Services of Cardinal Health, Inc. Ms. Olson serves as President of Nuclear Pharmacy Services of Cardinal Health 414, LLC. Ms. Olson leads a network of 137 nuclear pharmacies and 37 positron emission tomography (PET) manufacturing sites that manufacture, compound, dispense and deliver patient doses annually. Prior to Cardinal Health, she served as President of NaviMed from 2011 to 2013. She served as Vice President of Diagnostics at Eli Lilly and Company, where she led the strategy development effort to create and commercialize diagnostics. She worked in the medical diagnostics and healthcare industry. She served as the Head of North America Operations at Roche Diagnostics Corporation from June 1, 2005 to 2008 and its President until 2008. She served as Chief Executive Officer of Roche Diagnostics Corporation and also served as its President. She joined Roche Diagnostics in 1997. She served as the Global Head of Market Development located in Basel, Switzerland, leading Global Market Development for Roche Diagnostics Division of Basel, Switzerland. While in Switzerland, her responsibilities included Divisional Quality and Regulatory Management, Clinical Development, Government Affairs and Market Development. Ms. Olson was the Owner of Resource Consulting Services. She has professional healthcare experience in healthcare industry. Her prior responsibilities at Roche Diagnostics include Vice President of Molecular Diagnostics, with responsibilities for sales, marketing and support for Roche's Molecular Diagnostics products in the U.S. She served as the Vice President of Corporate Accounts and Business Development Manager for Roche Diagnostics Corporation (USA) of Indianapolis Ind. She has a depth of experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceutical sector. She was the first woman to receive the Life Science Alley Luminary Award. She served as the Chairman and Member of Board of Advisors at Diaceutics Limited from November 15, 2011 to December 17, 2013. She has been a Director of Asuragen, Inc. since January 17, 2017. Ms. Olson served as an Independent Director of Ativa Medical Corporation. Ms. Olson serves on the boards of Langham Logistics and The Education and Research Foundation for Nuclear Medicine and Molecular Imaging. She served as a Director of Cesca Therapeutics Inc. from August 1, 2008 to March 31, 2010. She served as a Director of Central Indiana Corporate Partnership (CICP), Indiana's Governors Education Round Table, Women in Biotechnology, Exosome Diagnostics, Inc. and AdvaMed. She served in leading positions with other healthcare providers. She serves as a Director at Community Health Network and Simon Youth Foundation. In 2013, she received the “10 Best Women Leaders of 2020” for her extraordinary contributions through her volunteer work in oncology. Ms. Olson holds an MBA from the University of St. Thomas (St.Paul, Minnesota) and a BS in Business from the University of Minnesota, School of Management.
公司职务
- 公司名称Castle Biosciences, Inc.股票代码CSTL职务Independent Director共事同僚
- DJDerek J. MaetzoldFounder, CEO, President & Director
- DMDaniel Mark BradburyIndependent Chairman of the Board
- FSFrank StokesCFO & Treasurer
- KMKristen M. OelschlagerChief Operating Officer
- TWTobin W. JuvenalChief Commercial Officer
- CZCamilla ZuckeroVice President of Investor Relations & Corporate Affairs
- GBGordon Bradley ColeIndependent Director
- EGEllen GoldbergIndependent Director
